Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib

Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib

Background: Gastric pH changes by proton-pump-inhibitors (PPIs) were found to affect progression-free survival (PFS) in metastatic breast cancer (mBC) patients treated with palbociclib. The current study was aimed at investigating whether the same effect could occur in patients treated with ribocicl...

Full description

Bibliographic Details
Main Authors: Marzia Del Re, Stefania Crucitta, Claudia Omarini, Irene Bargagna, Marta Mongillo, Michela Palleschi, Stefania Stucci, Icro Meattini, Raffaella D'Onofrio, Giulia Lorenzini, Pamela Biondani, Ugo De Giorgi, Camillo Porta, Lorenzo Livi, Salvatore Natalizio, Andrea Fontana, Elena Giontella, Lucia Angelini, Stefano Fogli, Romano Danesi
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:Breast
Subjects:
Breast cancer
Ribociclib
Proton pump inhibitors
Drug-drug interactions
PFS
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977622001709

Internet

http://www.sciencedirect.com/science/article/pii/S0960977622001709

Similar Items